Tyra Selects 60mg Dose of Dabogratinib in NMIBC Phase 2 Study

Tyra Biosciences selected a 60mg once daily dose of dabogratinib for its Phase 2 study SURF302 targeting FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer, aiming to offer an oral alternative to intravesical treatment. The dose choice signals clinical proof of concept for selective oral FGFR3 inhibition, with further enrollment and readouts required to confirm its registration potential.

This Wire brief sits within Fusion42's coverage of Biotech.